immunotherapy

//immunotherapy

One Man’s Shares His Personal Tips About Having Provenge To Treat His Advanced Prostate Cancer

The following was posted on the Malecare Advanced Prostate Cancer Health Unlocked online support group.  I have received permission to reprint it here because it might be helpful to some of you. FYI-    Provenge is a cancer vaccine that helps to mobilize your own immune system to your prostate cancer.  It is currently only approved in the United States for men who castrate resistant. It is administered by first removing a bag of your white blood cells, sending them off to a factory in Seale Beacj Calif. where the white cells (T cells) are altered by having a protein [...]

It Is Clear Who Should Take Provenge And Who Should Not

Provenge, despite its demonstrated survival advantage continues to be knocked as a viable treatment for men with castrate resistant prostate cancer. Why is this the case? First,  Provenge does not affect the PSA. Most men will continue to see their PSA rise, as well as their disease progress based on scans, while they take the treatment. Remember, the total treatment time is one month long. Many of our other treatments do affect the PSA, so many men believe that Provenge is nothing more than a placebo. However, I have been saying that not all men are in fact candidates for [...]

Updated Overall Survival Data from a Phase 3 Trial of Ipilimumab vs. Placebo in Men Post Chemotherapy Receiving Radiation Therapy – Still Needs Time

Presented in a poster at the recent European Society of Medical Oncologist (ESMO) there was a data update of the phase 3 clinical trial (CA184-043) which evaluated overall survival (OS) in men having radiotherapy (RT) followed by either the immunologic drug Ipilimumab (Ipi) or with a placebo. Initially, this trial did not meet its endpoint and was considered to have failed (Kwon ED, et al. Lancet Oncol 2014 in press). This update included an additional year of data. In the trial 799 men were randomized to receive a single dose of RT to their bone metastases followed by either Ipi [...]

On The Horizon – Tasquinimod – Immunotherapy & An Anti-Angiogenic Agent

In my commitment to report “On the Horizon” treatments for advanced prostate cancer today I will discuss an investigational treatment known as Tasquinimod. It is an experimental treatment that is both an immunotherapy and anti-angiogenic agent (designed to prevent the development of blood vesicles which would feed a tumor allowing its growth). In phase 2 clinical trials it has shown its ability to prolong progression-free survival (PFS) and also overall survival (OS) in certain men with metastatic castration-resistant prostate cancer (mCRPC). Researcher at Duke University reported that in more than 2 years men who participated in the randomized, placebo-controlled trial [...]